Metronomics Global Health Initiative

Dr Sidharth K TODARI

2020-06-26T10:59:22Z

Dr. Sidharth K Totadri completed his MD in pediatrics and DM in Pediatric Hematology Oncology from the Post Graduate Institute of Medical Research in Chandigarh, India. He further worked as a senior research associate there for 2.5 years after which he joined as an assistant Professor in the Pediatric Hematology Oncology unit of the Christian Medical College and Hospital, Vellore, India.

He manages children with benign hematological disorders such as hemolytic anemias and bleeding disorders, and malignancies including leukemias, lymphomas and solid tumors.

He was awarded the PODC scholarship and Fasanelli award for the best paper on bone sarcomas at the SIOP 2018 conference held in Tokyo, Japan.

DR. Lawrence OSEI-TUTU

2020-01-03T14:25:09Z

Dr. Lawrence Osei-Tutu completed his post-graduate fellowship training in clinical Paediatric Haematology and Oncology in 2017 at the University of Cape Town (UCT), South Africa to earn post-graduate diploma in clinical Paediatric Haematology and Oncology (awarded on December 14 2018). He qualified as a general paediatrician as a member of both the West African College of Physicians (WACP) and the Ghana College of Physicians (GCP) in 2013 and is a registered specialist paediatrician with the Medical and Dental Council of Ghana.

Dr. Osei-Tutu currently heads the Paediatrics department of the Presbyterian Hospital, Agogo (the largest Mission Hospital in Ghana) in the Asante-Akyem North District of the Ashanti region of Ghana on secondment from the Paediatric Haematology/Oncology Unit of the Child Health Department of the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana (second largest teaching hospital in Ghana). Dr. Osei-Tutu has the experience of providing specialist clinical services in malignant and non-malignant paediatric haematological and oncological conditions at both the primary and tertiary Ghanaian settings.

He has a keen interest in the treatment of malignant and non-malignant paediatric haematological diseases in low- and middle-income countries. His short years of experience practicing in low income settings where late presentation, advanced disease and financial toxicity characterize paediatric Haematology/Oncology practice, has nurtured his growing interest in the field of metronomic therapy and drug repurposing for paediatric cancer treatment. His other interests include quality improvement in health care and global health. He is a member of the African Cancer Coalition's working group that harmonized the National Comprehensive Cancer Network's (NCCN) protocol on Paediatric Acute Leukaemia.

Dr. Osei-Tutu has a few conference abstract and poster publications in paediatric Haematology/Oncology epidemiology; clinical care; palliative and end-of-life care.

Lisa HUTCHINSON

2017-08-03T13:17:32Z

Lisa Hutchinson obtained a first class honours BSs degree in Biochemistry from University College London, and received her PhD from the Institute of Cancer Research, London, under the supervision of Dr Michael J. Fry, where her research focused on the biochemical analysis of components of the Wg/Wnt signalling pathway in breast cancer.

Lisa then left the bench to pursue her career in publishing, and in 1999 joined Current Science Ltd as Assistant Editor of the journal Breast Cancer Research. She was promoted to the Editor after 1 year.
In 2002, she joined Wells Healthcare Limited as Senior Editor working on a number of projects in the fields of hepatology, diabetes, chronic wound care, and drug addiction.

Lisa joined the Nature Reviews department in 2004 and has been the Chief Editor of Nature Reviews Clinical Oncology until September 2017.

Pr Amany MOHAMED ALI

2017-03-09T17:14:07Z

Pr Amany Mohamed Ali is Associate Professor of Pediatric Oncology. She is currently the Head of the Department of Pediatric Oncology, South Egypt Cancer Institute, in the Assiut University, EGYPT

She completed her Master degree of general pediatric in 1996 and MD degree of pediatric oncology in 2007

She has working in the Pediatric Oncology at Pediatric Oncology Department, Assiut University, South Egypt Cancer Institute (SECI) from 1996 to now.

She is also the Coordinator of Academic teaching standard of pediatric oncology in Quality Assurance Unit of South Egypt Cancer Institute and member of the Scientific Research Unit, the Ethical committee, the postgraduate studies and research committee and the Institute council of South Egypt Cancer Institute.

She has recently completed and published a trial about the combination of metronomic chemotherapy and radiotherapy as a palliative approach.

Dr. Chi-kong LI

2016-12-02T18:11:41Z

Dr. Chi-kong Li is currently the Director of Lady Pao Children's Cancer Centre, Prince of Wales Hospital and Professor of The Chinese University of Hong Kong.

He graduated from the University of Hong Kong in 1981, and obtained Doctor of Medicine from The Chinese University of Hong Kong in 2002. He then received general paediatric training in Hong Kong, and specialised in paediatric Haematology/oncology/BMT with further training at United Kingdom and USA.
He had been Chief of Service of Department of Paediatrics, Prince of Wales Hospital for from 2004 to 2014.

His main research interest is in childhood leukaemia, haematopoietic stem cell transplantation and thalassaemia. Dr Li has close collaboration with hospitals in China

Dr Chi-Kong Li is now the vice chairman of the Chinese Children Cancer Group, and also member of haematology section of The Chinese Pediatric Association. He also takes up the Continental President of Asia, International Society of Pediatric Oncology in 2015. He has published over 280 peer-reviewed papers, written chapters in 3 books and editor of one book.

Dr Kelvin K. TSAI

2016-11-29T17:30:08Z

Dr. Tsai (M.D., Ph.D.) is a rigorously trained physician-scientist focusing on basic and translational research in cancer.

He specializes in tumor epigenetics, tissue architecture, therapeutic resistance and cancer stemness, with a career goal aiming at targeting and treating metastasis and treatment resistance, the two major reasons for cancer mortality.

Dr. Tsai graduated with a MD in 1993 from Taipei Medical University, Taiwan, and completed his clinical training and was board certified in internal medicine, gastroenterology and GI oncology. Dr. Tsai earned his PhD in 2005 in Genetics and Complex Diseases from Harvard University, USA.

During his PhD work Dr. Tsai established novel three-dimensional coculture models to interrogate stromal-epithelial interactions. In 2007, he joined Valerie M. Weaver's Laboratory at UCSF to study a novel epigenetic mechanism in cancer drug resistance. Following his postdoc research Dr. Tsai funded the Laboratories for Tumor Aggressiveness and Stemness (The TAS Lab) and rose to the Associate Investigator at National Institute of Cancer Research in National Health Research Institutes, Taiwan.

He has published first or corresponding author papers in top-notch journals such as Gastroenterology, JACC, Gut, and JEM. His major scientific achievements include the identification of a novel regulator for Wnt signaling and cancer stem cells, ASPM, and a master regulator of de novo treatment resistance in most cancers, N-CoR2. Dr. Tsai's breakthrough findings along these lines of research have yielded a number of issued or pending global patents and he is now actively collaborating with academic and industrial sectors worldwide aiming at developing novel cancer therapeutics.

Pr LEUNG Ping Chung

2016-08-26T12:59:14Z

Prof. LEUNG Ping-Chung, SBS, OBE, JP, Hon DSSc, DSC, MBBS, MS, FRACS, FRCS(Edin), FHKCOS, FHKAM(Orth); is Founding Chairman and Emeritus Professor of Orthopaedics and Traumatology, Faculty of Medicine, Director of Centre for Clinical Trials on Chinese Medicine, and Director of the Institute of Chinese Medicine, The Chinese University of Hong Kong.
Prof. Leung's research areas including Orthopaedics, Osteoporosis, Microsurgery Health, Traditional Chinese Medicine and General Education.

He is also the author of over over 900 scientific manuscripts in peer reviewed journals, 11 books and 95 books chapters. Examples of publication related in Chinese medicine include: “A Comprehensive Guide to Chinese Medicine”, ”Book in preparation: A Scientist View on Traditional Chinese Medicine”, “Limb Salvage for Diabetic Ulceration with Traditional Chinese techniques”, “Treatment of Low Back Pain with Acupuncture” etc. In addition, he also holds 5 patents.

Prof. Leung has also been appointed as editor or member of the editorial board of of 30 international medical journals since 1982.

Prof. Leung has been awarded many different kinds of honors, such as Humanity Award (2009), People Award for Outstanding Contribution of Rehabilitation on China(中國康協肢殘康復第 18 屆年會 2009 年度突出貢獻人物獎)(2009), Gusi Peace Prize (2006), Far Eastern Economic Review – Asian Innovation Silver Award (2000), Award for National Harmony of the State Council of the People's Republic of China(中華人民共和國國務院民族和諧獎)(2000), Order of the British Empire (1995) and Liston Victoria Jubilee Prize by Royal College of Surgeons (1990).
In his capacity of the Director of the Institute of Chinese Medicine, Prof. Leung has put enormous efforts in modernizing traditional Chinese medicine.

He has adopted the Efficacy Driven Approach in Clinical Trials. Currently, there are more than 30 clinical trials research projects underway in the Institute of Chinese Medicine. Extensive network has been developed internationally. Notable international collaborations include two NIH international grants with Harvard University, and Memorial Sloan Kettering Cancer Centre, CNRS of France, etc.

Bishal Gyawali

2016-07-15T09:18:22Z

Dr. Bishal Gyawali received his MBBS degree from the Institute of Medicine, Tribhuwan University, Nepal in 2011 with seven gold medals for his academic excellence. He has been honored with “Student of the Decade award” and “Best Student Award” for his academic excellence in Nepal.

Dr. Gyawali is currently undergoing his postgraduate training in medical oncology at the Graduate School of Medicine, Nagoya University, Japan, where he is also a PhD candidate under the Japanese government scholarship. He also serves as visiting faculty at the department of Hemato-Oncology in Nobel Hospital, Kathmandu, Nepal.

His areas of interest include evidence-based oncology practice, cost-effectiveness of cancer therapies and economic feasibility of cancer management in low-income countries, including metronomic therapy. He has published more than 20 peer-reviewed oncology articles, editorials, commentaries and letters in medical journals including NEJM, Lancet Oncology and Journal of Clinical Oncology. He also serves as reviewers for journals such as Annals of Internal Medicine, Journal of Global Oncology, Cancer Science, etc.

He is a member of the American Society of Clinical Oncology, European Society of Medical Oncology, Japanese Society of Medical Oncology and International Association for the Study of Lung Cancer.

He blogs “Last Month in Oncology with Dr. Bishal Gyawali” at ecancer and tweets @oncology_bg

He has launched the MGHI facebook page and will be in charge of it.

DR Ramaswami KARTIK

2016-05-02T20:47:00Z

R. Kartik obtained first class honours BSc (1998) and MSc (2000) degree in Zoology from Sambalpur University, Orissa, India and obtained PhD (2007) in Zoology from National Botanical Research Institute (CSIR), Lucknow, Uttar Pradesh, India under the supervision of DR Ch. V .Rao and Dr S.P.Trivedi, from University of Lucknow where his research focus on development and screening of medicinal plants screening on hepatocellular carcinoma.
He then worked as application specialist in molecular biology for applied Biosystems for All-essa medical and scientific equipment Co based in Kuwait from 2006-2008. I offered a post-doctoral fellowship under Department of Biotechnology, Govt of India in 2009-10 where the focus of research in the area of tumor biology to study the role of EMT pathway in Oral squamous cell carcinoma.
I then a short stint as second post-doctoral in 2011 in Department of dermatology in Indian University school of medicine, Indianapolis, USA where the research focus on elucidating and validating of compound screening for development of drug for spinal muscular atropy.
He worked as a consultant (molecular biology) from June 2011- Feb 2012 for Food Tech International, Mangalore, India and joined as principal scientist for an oceanic edible international limited to head a laboratory for food testing (2012-14) and quality assurance and control.
He works as a consultant, biotechnology research for hydrocarbon solution private limited (2014-2015), and was involved in designing, execution, implementation of state of art laboratory projects, proposal on research in field of biotechnology, life sciences and food biotechnology. All the related to projects focus in promoting our channel partner company Agilent Technologies.

In 2016, he joined as Clinical programme management executive in HLL life care limited in R&D for the development programme on project related to women and child health care.

John EBOS

2015-04-01T10:57:00Z

John Ebos (PhD) is an Assistant Professor of Oncology in the Departments of Cancer Genetics and Medicine at Roswell Park Cancer Institute (RPCI), and is a member of the graduate faculty in the Department of Pharmacology and Therapeutics at the State University of New York at Buffalo.

Dr. Ebos completed his undergraduate training at McGill University and earned his PhD in the Department of Medical Biophysics at the University of Toronto under the mentorship of Dr. Robert S. Kerbel where he studied novel circulating molecules as potential surrogate markers of cancer progression and antiangiogenic drug efficacy.

Dr. Ebos doctoral studies led to the discovery of a soluble form of a key receptor for the vascular endothelial growth factor (VEGF) pathway, the ligand/receptor pairing that is the central target for all antiangiogenic therapies now FDA approved in several different cancer types. This soluble receptor (termed ‘sVEGFR-2'), along with several other circulating cytokines, were then studied as indicators of off-target ‘host' effects following therapy and investigated for their potential to facilitate disease progression.

Dr. Ebos' laboratory currently focuses on the molecular mechanisms that drive intrinsic and acquired drug resistance to stromal inhibitors in the treatment of spontaneous metastatic disease in mouse surgical models. This includes late-stage systemic metastasis as well as early-stage perioperative settings, such as with adjuvant and neoadjuvant treatment settings. The long-term goal of these efforts is to conduct preclinical models in conjunction with ongoing clinical trials so that benefits can be more readily predicted and rational designs for subsequent/alternative therapies can be developed.